Kyverna Therapeutics (KYTX) Non-Current Assets (2023 - 2026)

Kyverna Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• Quarterly Non-Current Assets rose 17.64% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (down 8.3% YoY) and the FY2025 annual result came in at $10.9 million, down 22.58% from the prior year.
• Non-Current Assets was $15.3 million for Q1 2026 at Kyverna Therapeutics, up from $10.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $15.3 million in Q1 2026 and bottomed at $10.9 million in Q4 2025.
• A 4-year average of $13.5 million and a median of $13.9 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2025 — Non-Current Assets slipped 22.58% — and 2026, when it grew 17.64%.
• Kyverna Therapeutics' Non-Current Assets stood at $14.5 million in 2023, then fell by 3.35% to $14.0 million in 2024, then slipped by 22.58% to $10.9 million in 2025, then soared by 40.7% to $15.3 million in 2026.
• Business Quant data shows KYTX's Non-Current Assets at $15.3 million in Q1 2026, $10.9 million in Q4 2025, and $12.2 million in Q3 2025.